Bioton
- Company typePrivate
- Founded1989
- HeadquartersOzarow Mazowiecki, Poland
- Headcount251–500
- GTM typeB2C
- OfferingHardware or Manufacturing
Bioton firmographics
Firmographics- Name
- Bioton
- Legal name
- BIOTON S.A.
- Website
- https://bioton.com
- Company type
- Private
- Founded year
- 1989
- Operating status
- Operating
- Headcount range
- 251–500 employees
- Ownership category
- akta.pro rank
Bioton industry classification
Industry- Product category
- Diabetes Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Insulin & Analog Biosimilars (HLAAAHAD)
- akta.pro secondary industries
- Biologic API/Drug Substance Manufacturing Services (HLAAAKAA), Packaging, Labeling & Serialization Services (biologics/cold chain) (HLAAAKAJ)
Keywords
Where Bioton is headquartered
LocationHeadquarters
- HQ city
- Ozarow Mazowiecki
- HQ country
- Poland
- HQ region
- Europe
Offices1 record
Markets served
Bioton business model
Business model- GTM type
- B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Technology or R&D, Personnel, Marketing or Sales
Distribution channels2 records
Marketing channels2 records
Bioton product offering
Product offeringCore offering
Bioton is a Polish biotechnological pharmaceutical company that manufactures and sells biosynthetic insulin products (Gensulin M30, Gensulin N, Gensulin R in 100 IU formulations) and the GensuPen automatic insulin injection device for diabetes treatment. The company operates its own GMP-compliant manufacturing facility in Macierzysz near Warsaw, handling the full insulin production cycle, and supports products with a direct patient education platform.
Product overview
Bioton is a pharmaceutical company offering complete diabetological solutions. Its product portfolio centers on insulin products (Gensulin) and an automatic injection device (GensuPen), supported by patient education services through the 'Zapytaj Specjalistę' platform. The company operates its own manufacturing facility in Macierzysz near Warsaw, where insulin synthesis and production take place.
Differentiator
Problem solved
Functional benefit
Brands
- Gensulin: Insulin product line including Gensulin M30, Gensulin N, and Gensulin R for diabetes treatment
- GensuPen
- Bioton Marketing Agency
- Biolek
Products and services
- Gensulin
Companies that use Bioton
Customer profileSegments2 records
Ideal customer profiles2 records
Bioton technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Bioton partnerships and signals
Strategic signalRecent moves6 records
Expansion highlights5 records
Bioton competitors and assessment
Company assessmentBroad incumbents
- Sanofi: Major insulin producer (Lantus, Toujeo, Apidra) with global diabetes commercial reach. Comparable to Bioton in the insulin manufacturing category, but Sanofi spans vaccines, rare disease, and immunology, making Bioton's pure-play diabetes focus a clear differentiation lens.
- Novo Nordisk: Global leader in insulin and diabetes care with a full analog insulin portfolio (NovoRapid, Levemir, Tresiba) and the dominant GLP-1 franchise (Ozempic). Comparable to Bioton as a vertically integrated insulin manufacturer, but operating at vastly greater scale and breadth across diabetes and obesity therapeutics.
- Eli Lilly: Manufacturer of Humalog, Humulin, and the new generation of diabetes/obesity therapies (Mounjaro, Zepbound). Comparable to Bioton as an insulin originator/biomanufacturer, with a vastly larger and more diversified therapeutic footprint.
Direct peers
- Biocon: India-based biopharmaceutical company with a leading global biosimilar insulin and analog franchise (Semglee, Insulin Glargine). The closest direct comparator to Bioton as a non-originator insulin biosimilar manufacturer competing in regulated markets, with a similarly integrated biologics manufacturing footprint.
- Tonghua Dongbao Pharmaceutical: China's largest insulin producer, focused on recombinant human insulin and insulin analogs. Comparable to Bioton as a dedicated insulin manufacturer with vertically integrated fermentation and fill-finish capability targeting emerging and regulated export markets.
- Gan & Lee Pharmaceuticals: Chinese insulin specialist producing insulin analogs (insulin glargine, lispro, aspart) and recombinant human insulin. Comparable to Bioton as an insulin-focused biomanufacturer with growing international registration ambitions and a portfolio bundled with injection devices.
Others
- Ypsomed: Swiss manufacturer of injection and infusion systems, including insulin pen platforms used by multiple insulin producers. Comparable to Bioton as a supplier of the pen-style delivery hardware (analogous to GensuPen) that complements biologic insulin franchises.
Emerging players
- Adocia: French clinical-stage biotech developing novel insulin formulations (e.g., BioChaperone insulin combinations) and partnered programs with global pharma. Comparable to Bioton as a diabetes-focused biotech, though Adocia operates upstream in formulation R&D rather than commercial manufacturing.
- Wockhardt: India-based pharmaceutical company with a dedicated insulin and biosimilars business supplying emerging markets. Comparable to Bioton as a non-originator insulin producer targeting cost-sensitive geographies with human insulin and biosimilar formulations.
Regional players
- Polpharma: Poland's largest pharmaceutical manufacturer and one of the leading generic producers in Central Europe. Comparable to Bioton as a domestic Polish pharma peer competing for HCP relationships, distribution channels, and government procurement, though Polpharma is broader in therapeutic scope and not insulin-specialized.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
Bioton social profiles
Digital presenceBioton financial estimates
Financial estimateRevenue estimate
Valuation estimate
Bioton leadership team
Management profileNumber of profiles
Bioton funding detail
Funding detailFunding overview
Funding rounds3 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Bioton M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Bioton
What does Bioton do?
Bioton is a Polish biotechnological pharmaceutical company that manufactures and sells biosynthetic insulin products (Gensulin M30, Gensulin N, Gensulin R in 100 IU formulations) and the GensuPen automatic insulin injection device for diabetes treatment. The company operates its own GMP-compliant manufacturing facility in Macierzysz near Warsaw, handling the full insulin production cycle, and supports products with a direct patient education platform.
Is Bioton a public or private company?
Bioton is a private company. It is classified as private equity controlled and is currently operating.
When was Bioton founded?
Bioton was founded in 1989. It employs 251 to 500 people.
Where is Bioton based?
Bioton is headquartered in Ozarow Mazowiecki, Poland, in the Europe region.
Who are Bioton's main competitors?
Broad incumbents on record are Sanofi, Novo Nordisk and Eli Lilly. Direct peers are Biocon, Tonghua Dongbao Pharmaceutical and Gan & Lee Pharmaceuticals. Ypsomed is listed as an others. Emerging players are Adocia and Wockhardt. Polpharma is listed as a regional player.
Does Bioton have an API?
No public API is recorded for Bioton.
What industry is Bioton in?
Bioton's product category is Diabetes Pharmaceuticals. Its primary akta.pro industry code is HLAAAHAD, Insulin & Analog Biosimilars, with a secondary code of HLAAAKAA, Biologic API/Drug Substance Manufacturing Services. Its NAICS code is 325414 and its SIC code is 2834.